Evidence map›Paper›PMID 31452745›Full record

ArticleOncology letters2019

Jia-Juan Hsieh, Ming-Mo Hou, John Wen-Cheng Chang, Yung-Chi Shen, Hsin-Yi Cheng, Todd Hsu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. MicroRNA-141-5p Acts as a Tumor SuppressorFrontiers in pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jia-Juan HsiehDepartment of Bioscience and Biotechnology and Center of Excellence for The Oceans, National Taiwan Ocean University, Keelung 20224, Taiwan, R.O.C.
Ming-Mo HouDivision of Hematology-Oncology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan, R.O.C.
John Wen-Cheng ChangDivision of Hematology-Oncology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan, R.O.C.
Yung-Chi ShenDepartment of Bioscience and Biotechnology and Center of Excellence for The Oceans, National Taiwan Ocean University, Keelung 20224, Taiwan, R.O.C.
Hsin-Yi ChengDivision of Hematology-Oncology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan, R.O.C.
Todd HsuDepartment of Bioscience and Biotechnology and Center of Excellence for The Oceans, National Taiwan Ocean University, Keelung 20224, Taiwan, R.O.C.
Chang Gung University · TWNational Taiwan Ocean University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ras-related protein Rab-38 (RAB38) is a member of the Ras small G protein family that regulates intracellular vesicular trafficking. Although the expression of

Indexed as

non-small cell lung cancerprognosisRas-related protein Rab-38

Identifiers

PMID31452745
PMCPMC6676642
OpenAlexW2953945747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.